Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Tiziana Life Sciences has announced that the last patient in its Phase 2a INFORM-MS trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS) has been dosed. This randomized, double-blind, placebo-controlled study is evaluating safety, tolerability, and efficacy of the drug in up to 48 patients across multiple …